Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zovirax in third-class-of-drugs

This article was originally published in The Tan Sheet

Executive Summary

APhA maintains in comments to FDA that by making Zovirax "available only through consultation with pharmacists" but without a prescription, many of the public health and safety concerns addressed at FDA's May 19 public hearing on the OTC switch of Burroughs Wellcome's anti-herpes treatment Zovirax (acyclovir) would be resolved ("The Tan Sheet" May 23, p. 1). APhA also suggested that while Zovirax is in the transitional class, Burroughs Wellcome would be able to continue clinical research on the drug. The California Pharmacists Association seconded APhA's recommendation, stating that acyclovir "be made available...only when a pharmacist is available to provide the patient with appropriate counseling"

Topics

UsernamePublicRestriction

Register

PS083016

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel